According to Fortune Business Insights, the global Transcatheter Pulmonary Valve Market was valued at USD 78.68 million in 2025 and is projected to grow from USD 83.08 million in 2026 to USD 128.40 million by 2034, registering a CAGR of 5.59% during 2026–2034. Rising prevalence of congenital heart disorders, increasing adoption of minimally invasive cardiac procedures, and advancements in transcatheter valve replacement technologies are supporting market growth.
Transcatheter pulmonary valve implantation is increasingly used to manage conditions such as pulmonary stenosis and pulmonary regurgitation, particularly among patients requiring right ventricular outflow tract reconstruction. Growing adoption of catheter-based procedures is also supported by shorter hospitalization periods and reduced surgical trauma compared with traditional interventions.
The increasing prevalence of congenital heart diseases and structural cardiac abnormalities is a major factor supporting market expansion. Conditions such as pulmonary stenosis and pulmonary regurgitation can require repeated valve interventions during a patient's lifetime. The growing use of transcatheter pulmonary valve implantation provides healthcare providers with a minimally invasive treatment option while supporting shorter recovery periods.
Pediatric cardiology programs and adult congenital heart disease clinics are also expanding, improving access to specialized cardiac interventions. Advancements in imaging technologies, catheter delivery systems, and valve durability are further supporting physician adoption.
Manufacturers are increasingly developing repositionable and self-expanding valve technologies designed to improve implantation precision. Advanced imaging guidance, 3D cardiac mapping, artificial intelligence, and digital cardiac imaging are also being integrated into structural heart programs.
Another important trend is the growing use of transcatheter pulmonary valve therapies among adults with congenital heart disease. Increasing survival among these patients is generating long-term demand for repeat pulmonary valve interventions. Hospitals are also establishing hybrid cardiac operating rooms and specialized structural heart programs to support minimally invasive procedures.
For detailed market insights, visit: https://www.fortunebusinessinsights.com/transcatheter-pulmonary-valve-market-117414
The growing preference for minimally invasive cardiovascular procedures is creating opportunities for valve manufacturers. Healthcare providers are increasingly adopting catheter-based interventions because they can reduce surgical trauma and hospitalization requirements.
Emerging healthcare economies are also investing in advanced cardiac care infrastructure, hybrid operating rooms, imaging technologies, and physician training programs. Innovation in biocompatible materials, repositionable valve systems, and smaller catheter delivery devices could further expand the addressable patient population.
Based on application, the market is divided into pulmonary stenosis and pulmonary regurgitation. Pulmonary regurgitation accounted for approximately 54% of the market, making it the leading application segment. Increasing demand for minimally invasive valve replacement among patients with repaired congenital heart defects is supporting this segment. Pulmonary stenosis accounted for approximately 46% of the market.
Based on technology, balloon-expandable valves accounted for approximately 58% of the market. Their controlled expansion, procedural stability, and accurate deployment make them widely used in specialized cardiac centers. Improvements in valve-frame durability and catheter flexibility are further supporting adoption.